Daxotel Indications/Uses

Breast cancer: DAXOTEL (Docetaxel) as monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
DAXOTEL (Docetaxel) in combination with Doxorubicin and Cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer.
DAXOTEL (Docetaxel) in combination with Doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not received prior chemotherapy.
DAXOTEL (Docetaxel) in combination with Capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.
DAXOTEL (Docetaxel) in combination with Trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER 2 and who previously have not received prior chemotherapy for metastatic disease.
Non-small cell lung cancer: DAXOTEL (Docetaxel) is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
DAXOTEL (Docetaxel) in combination with Cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Gastric adenocarcinoma: DAXOTEL (Docetaxel) in combination with Cisplatin and 5-fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarinoma of the gastro esophageal junction, who have not received prior chemotherapy for advanced disease.
Head and neck cancer: DAXOTEL (Docetaxel) in combination with Cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Prostate cancer: DAXOTEL (Docetaxel) in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.